Involvement of ICAM-1 in bone metabolism: A potential target in the treatment of bone diseases?

Expert Opinion on Biological Therapy

Volumn 5, Issue 3, 2005, Pages 313-320

  Lavigne, Patrick ^a   Benderdour, Mohamed ^a   Shi, Qin ^a   Lajeunesse, Daniel ^b   Fernandes, Julio C ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adhesion blockade; Bone diseases; ICAM 1; Treatment

Indexed keywords

CD11B ANTIGEN; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

BONE DISEASE; BONE METABOLISM; CELL INTERACTION; DISEASE ACTIVITY; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATORY CELL; MOLECULAR INTERACTION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; RECEPTOR BLOCKING; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; BONE AND BONES; BONE DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1;

EID: 17144364962     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.3.313     Document Type: Review

References (75)

1. SMITH CW, MARLIN SD, ROTHLEIN R, TOMAN C, ANDERSON DC: Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J. Clin. Invest. (1989) 83(6):2008-2017.
2. STAUNTON DE, DUSTIN ML, ERICKSON HP, SPRINGER TA: The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell (1990) 61(2):243-254.
3. SPRINGER TA: Adhesion receptors of the immune system. Nature (1990) 346(6283):425-434.
4. VAN DE STOLPE A, VAN DER SAAG PT: Intercellular adhesion molecule-1. J. Mol. Med. (1996) 74(1):13-33.
5. POBER JS, BEVILACQUA MP, MENDRICK DL et al.: Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J. Immunol. (1986) 136(5):1680-1687.
6. POBER JS, GIMBRONE MA JR, LAPIERRE LA et al.: Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J. Immunol. (1986) 137(6):1893-1896.
7. DUSTIN ML, ROTHLEIN R, BHAN AK, DINARELLO CA, SPRINGER TA: Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. (1986) 137(1):245-254.
8. PETRUZZELLI L, TAKAMI M, HUMES HD: Structure and function of cell adhesion molecules. Am. J. Med. (1999) 106(4):467-476.
9. POLVERINI PJ: Role of the macrophage in angiogenesis-dependent diseases. EXS (1997) 79:11-28.
10. YASUDA M, SHIMIZU S, OHHINATA K et al.: Differential roles of ICAM-1 and E-selectin in polymorphonuclear leukocyte-induced angiogenesis. Am. J. Physiol. Cell Physiol. (2002) 282(4):C917-C925.
11. CHAMPAGNE B, TREMBLAY P, CANTIN A, ST PIERRE Y: Proteolytic cleavage of ICAM-1 by human neutrophil elastase. J. Immunol. (1998) 161(11):6398-6405.
12. WAKATSUKI T, KIMURA K, KIMURA F et al.: A distinct mRNA encodings soluble form of ICAM-1 molecule expressed in human tissues. Cell Adhes. Commun. (1995) 3(4):283-292.
13. WHITEMAN SC, BIANCO A, KNIGHT RA, SPITERI MA: Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectiviry. J. Biol. Chem. (2003) 278(14):11954-11961.
14. MARLIN SD, STAUNTON DE, SPRINGER TA et al.: A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature (1990) 344(6261):70-72.
15. GHO YS, KLEINMAN HK, SOSNE G: Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res. (1999) 59(20):5128-5132.
16. KURACHI T, MORITA I, MUROTA S: Involvement of adhesion molecules LFA-1 and ICAM-1 in osteoclast development. Biochim. Biophys. Acta (1993) 1178(3):259-266. Description of ICAM-1 implication in Oc development.
17. TANAKA Y, MORIMOTO I, NAKANO Y et al.: Osteoblasts are regulated by the cellular adhesion through ICAM-1 and VCAM-1. J. Bone Miner. Res. (1995) 10(10):1462-1469.
18. + Ob in Oc development.
19. TANI-ISHII N, PENNINGER JM, MATSUMOTO G, TERANAKA T, UMEMOTO T: The role of LFA-1 in osteoclast development induced by co-cultures of mouse bone marrow cells and MC3T3-G2/PA6 cells. J. Periodontal Res. (2002) 37(3):184-191.
20. TAICHMAN RS: Blood and Bone: two tissues whose fates are intertwined to create the hematopoietic stem cell niche. Blood (2004) (In Press).
21. LISIGNOLI G, TONEGUZZI S, PIACENTINI A et al. Recruitment and proliferation of T lymphocytes is supported by IFNgamma- and TNFalpha-activated human osteoblasts: Involvement of CD54 (ICAM-1) and CD106 (VCAM-1) adhesion molecules and CXCR3 chemokine receptor. J. Cell. Physiol. (2004) 198(3):388-398.
22. LAVIGNE P, BENDERDOUR M, LAJEUNESSE D, SHI Q, FERNANDES JC: Expression of ICAM-1 by osteoblasts in healthy individuals and in patients suffering from osteoarthritis and osteoporosis. Bone (2004) 35(2):463-470.
23. GOLDRING SR, GRAVALLESE EM: Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res. (2000) 2(I):33-37.
24. JALKANEN S: Leukocyte-endothelial cell interaction and the control of leukocyte migration into inflamed synovium. Springer Semin. Immunopathol. (1989) 11(2):187-198.
25. ISHIKAWA H, NISHIBAYASHI Y, KITA K et al.: Adhesion molecules in the lymphoid cell distribution in rheumatoid synovial membrane. Bull. Hosp. Jt Dis. (1993) 53(2):23-28.
26. EL-GABALAWY H, GALLATIN M, VAZEUX R, PETERMAN G, WILKINS J: Expression of ICAM-R (ICAM-3), a novel counter-receptor for LFA-1, in rheumatoid and nonrheumatoid synovium. Comparison with other adhesion molecules. Arthritis Rheum. (1994) 37(6):846-854.
27. SZEKANECZ Z, HAINES GK, LIN TR et al.: Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum. (1994) 37(2):221-231.
28. ISHIKAWA H, HIRATA S, NISHIBAYASHI Y et al.: The role of adhesion molecules in synovial pannus formation in rheumatoid arthritis. Clin. Orthop. (1994) (300):297-303.
29. HALE LP, MARTIN ME, MCCOLLUM DE et al.: Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. Arthritis Rheum. (1989) 32(1):22-30.
30. JOHNSON BA, HAINES GK, HARLOW LA, KOCH AE: Adhesion molecule expression in human synovial tissue. Arthritis Rheum. (1993) 36(2):137-146.
31. TESSIER P, AUDETTE M, CATTARUZZI P, MCCOLL SR: Up-regulation by tumor necrosis factor alpha of intercellular adhesion molecule 1 expression and function in synovial fibroblasts and its inhibition by glucocorticoids. Arthritis Rheum. (1993) 36(11):1528-1539.
32. LINDSLEY HB, SMITH DD, COHICK CB, KOCH AE, DAVIS LS: Proinflammatory cytokines enhance human synoviocyte expression of functional intercellular adhesion molecule-1 (ICAM-1). Clin. Immunol. Immunopathol. (1993) 68(3):311-320.
33. BEVILACQUA MP, POBER JS, WHEELER ME, COTRAN RS, GIMBRONE MA JR: Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J. Clin. Invest. (1985) 76(5):2003-2011.
34. CHIN JE, WINTERROWD GE, KRZESICKI RF, SANDERS ME: Role of cytokines in inflammatory synovitis. The coordinate regulation of intercellular adhesion molecule 1 and HLA class I and class II antigens in rheumatoid synovial fibroblasts. Arthritis Rheum. (1990) 33(12):1776-1786.
35. WICKS IP, LEIZER T, WAWRYK SO et al.: The effect of cytokines on the expression of MHC antigens and ICAM-1 by normal and transformed synoviocytes. Autoimmunity (1992) 12(1):13-19.
36. BLANN AD, HERRICK A, JAYSON MI: Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br. J. Rheumatol. (1995) 34(9):814-819.
37. CUSH JJ, ROTHLEIN R, LINDSLEY HB, MAINOLFI EA, LIPSKY PE: Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum. (1993) 36(8):1098-1102.
38. KURYLISZYN-MOSKAL A, BERNACKA K, KLIMIUK PA: Circulating intercellular adhesion molecule 1 in rheumatoid arthritis-relationship to systemic vasculitis and microvascular injury in nailfold capillary microscopy. Clin. Rheumatol. (1996) 15(4):367-373.
39. MASON JC, KAPAHI P, HASKARD DO: Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Lack of correlation with levels of circulating vascular cell adhesion molecule 1. Arthritis Rheum. (1993) 36(4):519-527.
40. NASSONOV EL, SAMSONOV MY, CHICHASOVA NV et al.: Soluble adhesion molecules in rheumatoid arthritis. Rheumatology (Oxford) (2000) 39(7):808-810.
41. MACHOLD KP, KIENER HP, GRANINGER W, GRANINGER WB: Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin. Immunol. Immunopathol. (1993) 68(1):74-78.
42. UGUR M, YILDIRIM K, KIZILTUNC A et al.: Correlation between soluble intercellular adhesion molecule 1 level and extracellular superoxide dismutase activity in rheumatoid arthritis: a possible association with disease activity. Scand J. Rheumatol. (2004) 33(4):239-243.
43. WAHL SM, ALLEN JB, HINES KL et al.: Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J. Clin. Invest. (1994) 94(2):655-662.
44. WITKOWSKA AM, KURYLISZYN-MOSKAL A, BORAWSKA MH, HUKALOWICZ K, MARKIEWICZ R: A study on soluble intercellular adhesion molecule-1 and selenium in patients with rheumatoid arthritis complicated by vasculitis. Clin. Rheumatol. (2003) 22(6):414-419.
45. HANYUDA M, KASAMA T, ISOZAKI T et al.: Activated leucocytes express and secrete macrophage inflammatory protein-1alpha upon interaction with synovial fibroblasts of rheumatoid arthritis via a beta2-integrin/ICAM-1 mechanism. Rheumatology (Oxford) (2003) 42(11):1390-1397.
46. NAKANO K, OKADA Y, SAITO K, TANAKA Y: Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum. (2004) 50(8):2450-2458.
47. NAKAYAMADA S, OKADA Y, SAITO K, TAMURA M, TANAKA Y: Beta1 integrin/focal adhesion kinase-mediated signaling induces intercellular adhesion molecule 1 and receptor activator of nuclear factor kappaB ligand on osteoblasts and osteoclast maturation. J. Biol. Chem. (2003) 278(46):45368-45374.
48. LAJEUNESSE D: The role of bone in the treatment of osteoarthritis. Osteoarthritis Cartilage (2004) 12(Suppl. A):S34-S38.
49. SMITH MD, SLAVOTINEK J, AU V et al.: Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression. Rheumatology (Oxford) (2001) 40(9):965-977.
50. DAVIES ME, DINGLE JT, PIGOTT R, POWER C, SHARMA H: Expression of intercellular adhesion molecule 1 (ICAM-1) on human articular cartilage chondrocytes. Connect. Tissue Res. (1991) 26(3):207-216.
51. IANNONE F, CORRADO A, GRATTAGLIANO V et al.: [Phenotyping of chondrocytes from human osteoarthritic cartilage: chondrocyte expression of beta integrins and correlation with anatomic injury]. Reumatismo (2001) 53(2):122-130.
52. LAPADULA G, IANNONE F, ZUCCARO C et al.: Chondrocyte phenotyping in human osteoarthritis. Clin. Rheumatol. (1998) 17(2):99-104.
53. LISIGNOLI G, GRASSI F, ZINI N et al.: Anti-Fas-induced apoptosis in chondrocytes reduced by hyaluronan: evidence for CD44 and CD54 (intercellular adhesion molecule 1) invovement. Arthritis Rheum. (2001) 44(8):1800-1807.
54. HORNER A, DAVIES ME, FRANZ B: Chondrocyte-peripheral blood mononuclear cell interactions: the role of ICAM-1. Immunology (1995) 86(4):584-590.
55. NO AUTHORS LISTED: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser. (1994) 843:1-129.
56. GAO Y, MORITA I, KUBOTA T, MUROTA S, ASO T: Expression of adhesion molecules LFA-1 and ICAM-1 on osteoclast precursors during osteoclast differentiation and involvement of estrogen deficiency. Climacteric (2000) 3(4):278-287.
57. PONTHIEUX A, HERBETH B, DROESCH S et al.: Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis (2004) 172(2):299-308.
58. CAULlN-GLASER T, FARRELL WJ, PFAU SE et al.: Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. J. Am. Coll. Cardiol. (1998) 31(7):1555-1560.
59. ANDERSON ME, SIAHAAN TJ: Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides (2003) 24(3):487-501. Review on adhesion molecule therapy in autoimmune diseases.
60. DEDRICK RL, BODARY S, GAROVOY MR: Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection. Expert Opin. Biol. Ther. (2003) 3(1):85-95. Review on adhesion molecule therapy in autoimmune diseases and transplant rejection.
61. YOUSSEF PP, TRIANTAFILLOU S, PARKER A et al.: Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression. Arthritis Rheum. (1996) 39(12):1970-1979.
62. KRAAN MC, REECE RJ, BARG EC et al.: Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. (2000) 43(8):1820-1830.
63. KRAAN MC, SMEETS TJ, VAN LOON MJ et al.: Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann. Rheum. Dis. (2004) 63(9):1056-1061.
64. CUTOLO M, SULLI A, GHIORZO P et al.: Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62(4):297-302.
65. KAVANAUGH AF, DAVIS LS, NICHOLS LA et al.: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. (1994) 37(7):992-999. ICAM-1 humanised mAb for RA treatment.
66. JASIN HE, LIGHTFOOT E, DAVIS LS et al.: Amelioration of antigen-induced arthritis in rabbits treated with monoclonal antibodies to leukocyte adhesion molecules. Arthritis Rheum. (1992) 35(5):541-549.
67. IIGO Y, TAKASHI T, TAMATANI T et al.: ICAM-1-dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats. J. Immunol. (1991) 147(12):4167-4171.
68. KAKIMOTO K, NAKAMURA T, ISHII K et al.: The effect of anti-adhesion molecule antibody on the development of collagen-induced arthritis. Cell. Immunol. (1992) 142(2):326-337.
69. KAVANAUGH AF, DAVIS LS, JAIN RI et al.: A Phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J. Rheumatol. (1996) 23(8):1338-1344. ICAM-1 humanised mAb for RA treatment.
70. KAVANAUGH AF, SCHULZE-KOOPS H, DAVIS LS, LIPSKY PE: Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. (1997) 40(5):849-853.
71. MAKSYMOWYCH WP, BLACKBURN WD JR, TAMI JA, SHANAHAN WR JR: A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis. J. Rheumatol. (2002) 29(3):447-453. ICAM-1 antisense therapy in RA treatment.
72. KARATAY S, KIZILTUNC A, YILDIRIM K, KARANFIL RC, SENEL K: Effects of different hyaluronic acid products on synovial fluid levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in knee osteoarthritis. Ann. Clin. Lab. Sci. (2004) 34(3):330-335.
73. AL-SAFFAR N, MAH JT, KADOYA Y, REVELL PA: Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants. Ann. Rheum. Dis. (1995) 54(3):201-208.
74. DAMBRA P, LORIA MP, MORETTI B et al.: Adhesion molecules in gonarthrosis and knee prosthesis aseptic loosening follow-up: possible therapeutic implications. Immunopharmacol. Immunotoxicol. (2003) 25(2):179-189.
75. NAKASHIMA Y, SUN DH, TRINDADE MC et al.: Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J. Bone Joint Surg. Am. (1999) 81(5):603-615.